EUVIMEDEUVIMED entdecken
Open Access

Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas

María Colmenero-Sendra, Javier Del Boz-González, Mercè Grau-Pérez, Ricardo Ruiz-Villaverde, Miguel Ángel Descalzo-Gallego, Ignacio García-Doval, Eulalia Baselga Torres

JAMA Dermatology · 2025

DOI: 10.1001/jamadermatol.2024.5125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2025. Verfasst von María Colmenero-Sendra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Costa del Sol, Marbella, Spain. Hauptthemen laut MEDLINE: Hemangioma, Skin Neoplasms, Practice Patterns, Physicians', Dermatologists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Although clinical practice guidelines exist for the treatment of infantile hemangiomas (IHs), recommendations are heterogeneous, and wide practice variations in IH management have been reported.

Objective

To analyze the degree of agreement in treatment choices for IH among pediatric dermatologists in North America and Europe and assess whether there are differences across IH risk categories. Design, Setting, and Participants This cross-sectional interrater and intrarater agreement study was conducted through a survey based on the Spanish Academy of Dermatology and Venereology IH prospective cohort. The survey used 50 vignettes of IH cases that were randomly selected from the cohort. It was administered twice in 2023, 1 month apart, to allow for interrater and intrarater agreement assessments. Data were analyzed in January 2024. The study involved pediatric dermatologists from North America (via the Pediatric Dermatology Research Alliance) and Europe (via the European Society of Pediatric Dermatologists). Exposures Participants were asked to choose 1 of 3 treatment options (propranolol, topical timolol, or observation) for each vignette. Main Outcome and Measure The primary outcome was the interrater agreement in treatment choices for IH cases, measured using κ statistics (Gwet AC1 coefficient).

Results

The global interobserver agreement among 90 pediatric dermatologists was fair (AC1, 0.38; 95% CI, 0.29-0.46). In North America (45 pediatric dermatologists), agreement was moderate (AC1, 0.41; 95% CI, 0.33-0.49), while in Europe (45 pediatric dermatologists) it was fair (AC1, 0.37; 95% CI, 0.28-0.46). The degree of agreement varied depending on the risk category of IH, with excellent agreement in high-risk IH and only moderate agreement in intermediate-risk and low-risk IHs. Propranolol was predominantly chosen for high-risk IH, while observation was most frequent for low-risk IH (55.9%). The second survey had 61 respondents, with no significant intrarater differences. Conclusions and Relevance The results of this survey study suggest that there is an important variability in the treatment of intermediate-risk and low-risk IH. The study findings support the need for more evidence regarding the role of topical timolol in IH treatment, which may help harmonize treatment approaches and improve consistency in IH management globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiomaSkin NeoplasmsPractice Patterns, Physicians'DermatologistsHumansCross-Sectional StudiesInfantObserver VariationTimololPropranololFemaleMaleProspective StudiesEuropeNorth AmericaAdministration, TopicalSurveys and Questionnaires

Substanzen

TimololPropranolol

Autor:innen und Institutionen

  • Dermatology Department, Hospital Costa del Sol, Marbella, Spain.
  • Programa de Doctorado en Medicina Clínica y Salud Pública, Universidad de Granada, Granada, Spain.
  • Dermatology Department, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Research Unit, Spanish Academy of Dermatology and Venereology, Madrid, Spain.
  • Dermatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.

Zitieren

APA

Colmenero-Sendra, M., Del Boz-González, J., Grau-Pérez, M., Ruiz-Villaverde, R., Descalzo-Gallego, M. Á., García-Doval, I., & Baselga Torres, E. (2025). Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.5125

Vancouver

Colmenero-Sendra M, Del Boz-González J, Grau-Pérez M, Ruiz-Villaverde R, Descalzo-Gallego MÁ, García-Doval I, et al. Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.5125

BibTeX
@article{ColmeneroSendra2025,
  author = {Colmenero-Sendra, María and Del Boz-González, Javier and Grau-Pérez, Mercè and Ruiz-Villaverde, Ricardo and Descalzo-Gallego, Miguel Ángel and García-Doval, Ignacio and Baselga Torres, Eulalia},
  title = {Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas},
  journal = {JAMA Dermatology},
  year = {2025},
  doi = {10.1001/jamadermatol.2024.5125}
}
Kostenlos starten →